Document is current
Any future updates will be listed below
-
Authors
Weisser, Nina E. https://orcid.org/0000-0002-9903-2429
Sanches, Mario https://orcid.org/0000-0003-3488-2526
Escobar-Cabrera, Eric
O’Toole, Jason
Whalen, Elizabeth
Chan, Peter W. Y.
Wickman, Grant
Abraham, Libin
Choi, Kate https://orcid.org/0000-0002-7959-1944
Harbourne, Bryant
Samiotakis, Antonios
Rojas, Andrea Hernández
Volkers, Gesa https://orcid.org/0000-0002-9901-0705
Wong, Jodi
Atkinson, Claire E.
Baardsnes, Jason
Worrall, Liam J.
Browman, Duncan
Smith, Emma E.
Baichoo, Priya
Cheng, Chi Wing
Guedia, Joy
Kang, Sohyeong
Mukhopadhyay, Abhishek
Newhook, Lisa
Ohrn, Anders
Raghunatha, Prajwal https://orcid.org/0000-0003-0435-4052
Zago-Schmitt, Matteo
Schrag, Joseph D.
Smith, Joel
Zwierzchowski, Patricia https://orcid.org/0000-0002-0087-6446
Scurll, Joshua M.
Fung, Vincent
Black, Sonia
Strynadka, Natalie C. J. https://orcid.org/0000-0002-4058-9425
Gold, Michael R. https://orcid.org/0000-0003-1222-3191
Presta, Leonard G.
Ng, Gordon
Dixit, Surjit
- License Information
-
More Information
Article History
Received: 8 March 2022
Accepted: 28 February 2023
First Online: 13 March 2023
Competing interests
: Zymeworks Inc. has filed patent applications relating to zanidatamab: PCT/CA2014/051140 (N.E.W., G.N., G.W., S.D., E.E.C., and M.S. are listed as inventors) and PCT/CA2015/051238 (N.E.W., G.N., G.W. are listed as inventors). These applications have issued in several jurisdictions, including the United States [US 10,000,576; US 10,947,319; US 11,325,981] and Japan [JP 6727379; JP 6817064; JP 6872482]. The other authors declare no competing interests.
